PTEN has been found to confer resistance to EGFR-inhibitors in glioblastoma, prostate, breast and non-small-cell lung cancer [15], and this resistance appears to be due to its function as a negative regulator of the phosphatidylinositol 3' kinase (PI3K) complex. Here, PTEN is linked to glioblastoma.